Lexie B2 Plus vs Otofonix Groove

The Lexie B2 Plus is a mid-priced OTC hearing aid that earns an A grade with a SoundScore of 4.4/5 in HearAdvisor's lab testing, ranking #7 among 65 OTC devices. Priced at $899, this behind-the-ear rechargeable device has earned back-to-back Expert's Choice Awards in 2023 and 2024. In our testing, the B2 Plus demonstrates strong speech-in-quiet performance at 4.3/5, which is 1.49 points above the OTC category average. Own-voice comfort is excellent at 4.8/5, measuring 2.29 points above average—a notable strength that may appeal to users who find their own voice bothersome with other devices. Speech-in-noise scores 2.1/5, which is above the category average by 0.58 points but remains mixed in absolute terms, reflecting the broader challenge OTC devices face in noisy environments. The device does show a weakness in feedback handling, scoring 2.8/5—which is 1.74 points below the category average of 4.54/5. Users may encounter occasional whistling during activities that bring objects close to the ear. Music streaming performance is mixed at 2.6/5, though still 0.68 points above the OTC average. The Lexie B2 Plus offers both iPhone and Android streaming compatibility. It's well-suited for users prioritizing clear speech in quieter settings and natural own-voice perception, though those frequently in noisy environments or concerned about feedback stability may want to consider alternatives like the Sony CRE-E10 in this price range.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.